In this large administrative database analysis, the use of recombinant Factor VIIa use in US hospitals from 2000 to 2008 increased by 140 fold, 97% of which were off-label in 2008. It was most commonly utilized for CV surgery, ICH, and trauma patients. All cause mortality among patients receiving it was 27% (abstract). In addition, a systematic review found that the use of FactorVII in a variety of conditions did not improve mortality, and did increase arterial thromboses (abstract). Hospitals should evaluate their use of rFactorVII to determine costs, risks, and benefits
Share This Post
Categories
Related Posts
Never let a good salary signal go to waste. Here is a meta-assembly of hospitalist, as well as comparator specialties, of 2018-19 salary moves courtesy of Modern Healthcare. It is useful seeing the various estimates from the leading consultants, placement firms, and intelligentsia to get some bearings on the pay trends, Covid notwithstanding.
This is the time of year to sit back at night, in front of the fireplace, a cup of hot chocolate in hand, warming up after the coolness of the day. As I sip, I notice the marshmallows bobbing up and down and reflect on the impact those white confections have in medicine. Yes, marshmallows […]
Look up from your stack of journals lately? You will note DNA analysis has gotten awfully popular. Mom, dad, and the rest of the clan want in and the temptation to obtain the blueprint that makes you, you has an almost hypnotic-like draw. You are curious if what grandma told you—half of your “G, C, […]
Leave A Comment